-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On July 28, Joincare announced that Livzon Pharmaceutical Factory, a wholly-owned subsidiary of the company's holding subsidiary Livzon Group, recently received the "Approval Notice for Supplementary Drug Application" approved and issued by the State Food and Drug Administrati.
, The isosorbide mononitrate tablets produced by Livzon Pharmaceutical Factory passed the quality and efficacy consistency evaluation of generic dru.
After review, this product passed the consistency evaluation of generic drug quality and effica.
It is reported that isosorbide mononitrate tablets are cardiovascular system drugs, which were first developed by German manufacturer Boehringer Mannheim, GmbH and launched in 198In China, Isosorbide Mononitrate Tablets are national essential medicines, and also a category A variety in the National Medical Insurance Drug Li.
They are used for long-term treatment of coronary heart disease; prevention of angina pectoris; treatment of persistent angina pectoris after myocardial infarction; combined with digitalis and/or diuretic Combined use of drugs for the treatment of chronic congestive heart failu.
As of the disclosure date of this announcement, the company's accumulated direct R&D expenses for the consistency evaluation of isosorbide mononitrate tablets amounted to approximately RMB 7,526,10From the perspective of market competition, at present, a total of 18 domestic companies hold the production approval for isosorbide mononitrate table.
It is worth mentioning that this variety has been included in the seventh batch of national centralized drug procurement list in July 2022, and 4 domestic companies have won the bid, including Yiling Pharmaceutical, Lunan Beite Pharmaceutical, Shandong Linuo Pharmaceutical, Shandong Fangfang Ming Pharmaceutical, e.
Among them, the winning bid price of Lunanbeite Pharmaceutical dropped by as much as 14
In terms of consistency evaluation, up to now, a total of 6 domestic enterprises have passed the consistency evaluation of this variety, including Livzon Pharmaceutical Factory, Qilu Pharmaceutical, Lepu Pharmaceutical, Lunanbeite Pharmaceutical, Lukang Pharmaceutical Saite Company,e.
The sales volume of isosorbide mononitrate tablets in pharmaceutical retail terminals is considerable and the dosage is hu.
According to IQVIA sampling statistics and estimation data, the terminal sales of domestic isosorbide mononitrate oral preparation products in 2021 will be approximately RMB 479 billi.
According to data from Min.
com, in 2021, the total sales of isosorbide mononitrate sustained-release tablets in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 1 billion yu.
The sales revenue of Livzon Pharmaceutical Factory's isosorbide mononitrate tablets in 2021 is approximately RMB 15,865,10The company said that passing the consistency evaluation this time will help improve the market competitiveness of the dr.
Since pharmaceutical products are characterized by high technology, high risk and high added value, and the sales of pharmaceuticals are easily affected by many unpredictable factors such as national policies and market environment, there are uncertainti.
Investors are advised to make decisions carefully and pay attention to investme.
ri.
According to public information, the business scope of Joincare covers chemical preparations, traditional Chinese medicine preparations, chemical raw materials and intermediates, diagnostic reagents and equipment, health food and other fiel.
The subsidiary Livzon Group is a comprehensive pharmaceutical group company integrating pharmaceutical R&D, production and sal.
It has continuously made breakthroughs in the fields of chemical drugs, biological drugs, in vitro diagnostic reagents, APIs, and traditional Chinese medicin.
Its products are distributed in digestive, cardiovascular and cerebrovascular fiel.
, reproductive endocrinology, mental / neurological and other fiel.
In recent years, Joincare has continued to increase its research and development efforts, and its research and development investment has increased significantly from 609 million yuan in 2016 to 850 billion yuan in 2021, and its research and development investment has tripled in five yea.
Among them, the company's expensed R&D investment in 2021 will reach 397 billion yuan, with a growth rate of over 3
With the rapid progress of research and development investment, in 2021, many key projects of the company will enter Phase III clinical trials, including V-01 and tobramycin inhalation soluti.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
, The isosorbide mononitrate tablets produced by Livzon Pharmaceutical Factory passed the quality and efficacy consistency evaluation of generic dru.
After review, this product passed the consistency evaluation of generic drug quality and effica.
It is reported that isosorbide mononitrate tablets are cardiovascular system drugs, which were first developed by German manufacturer Boehringer Mannheim, GmbH and launched in 198In China, Isosorbide Mononitrate Tablets are national essential medicines, and also a category A variety in the National Medical Insurance Drug Li.
They are used for long-term treatment of coronary heart disease; prevention of angina pectoris; treatment of persistent angina pectoris after myocardial infarction; combined with digitalis and/or diuretic Combined use of drugs for the treatment of chronic congestive heart failu.
As of the disclosure date of this announcement, the company's accumulated direct R&D expenses for the consistency evaluation of isosorbide mononitrate tablets amounted to approximately RMB 7,526,10From the perspective of market competition, at present, a total of 18 domestic companies hold the production approval for isosorbide mononitrate table.
It is worth mentioning that this variety has been included in the seventh batch of national centralized drug procurement list in July 2022, and 4 domestic companies have won the bid, including Yiling Pharmaceutical, Lunan Beite Pharmaceutical, Shandong Linuo Pharmaceutical, Shandong Fangfang Ming Pharmaceutical, e.
Among them, the winning bid price of Lunanbeite Pharmaceutical dropped by as much as 14
In terms of consistency evaluation, up to now, a total of 6 domestic enterprises have passed the consistency evaluation of this variety, including Livzon Pharmaceutical Factory, Qilu Pharmaceutical, Lepu Pharmaceutical, Lunanbeite Pharmaceutical, Lukang Pharmaceutical Saite Company,e.
The sales volume of isosorbide mononitrate tablets in pharmaceutical retail terminals is considerable and the dosage is hu.
According to IQVIA sampling statistics and estimation data, the terminal sales of domestic isosorbide mononitrate oral preparation products in 2021 will be approximately RMB 479 billi.
According to data from Min.
com, in 2021, the total sales of isosorbide mononitrate sustained-release tablets in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 1 billion yu.
The sales revenue of Livzon Pharmaceutical Factory's isosorbide mononitrate tablets in 2021 is approximately RMB 15,865,10The company said that passing the consistency evaluation this time will help improve the market competitiveness of the dr.
Since pharmaceutical products are characterized by high technology, high risk and high added value, and the sales of pharmaceuticals are easily affected by many unpredictable factors such as national policies and market environment, there are uncertainti.
Investors are advised to make decisions carefully and pay attention to investme.
ri.
According to public information, the business scope of Joincare covers chemical preparations, traditional Chinese medicine preparations, chemical raw materials and intermediates, diagnostic reagents and equipment, health food and other fiel.
The subsidiary Livzon Group is a comprehensive pharmaceutical group company integrating pharmaceutical R&D, production and sal.
It has continuously made breakthroughs in the fields of chemical drugs, biological drugs, in vitro diagnostic reagents, APIs, and traditional Chinese medicin.
Its products are distributed in digestive, cardiovascular and cerebrovascular fiel.
, reproductive endocrinology, mental / neurological and other fiel.
In recent years, Joincare has continued to increase its research and development efforts, and its research and development investment has increased significantly from 609 million yuan in 2016 to 850 billion yuan in 2021, and its research and development investment has tripled in five yea.
Among them, the company's expensed R&D investment in 2021 will reach 397 billion yuan, with a growth rate of over 3
With the rapid progress of research and development investment, in 2021, many key projects of the company will enter Phase III clinical trials, including V-01 and tobramycin inhalation soluti.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
